An assessment by the Statin Cognitive Safety Task Force: 2014 update
- PMID: 24793442
- DOI: 10.1016/j.jacl.2014.02.013
An assessment by the Statin Cognitive Safety Task Force: 2014 update
Abstract
The National Lipid Association's Safety Task Force convened a consensus conference of experts to develop a position statement on cognitive function to revise and update that published originally by the Association in the 2006 assessment of statin safety by a panel of neurologists. The current expert panel was charged with addressing the specific issue of potential adverse cognitive effects attributable to statins. Search strategies recently used in systematic reviews were used to identify relevant evidence using keywords and topics via Medline searches from 1966 to December 2013. Manual searches of bibliographies were also conducted. Panel members were asked to use the evidence to formulate answers to a series of questions of relevance to the subject matter. The strength of recommendations and quality of evidence were graded using accepted contemporary definitions and procedures. Recommendations to patients, health professionals, and researchers were put forth by the panel to aid in daily clinical decision making, and in future research endeavors.
Keywords: Adverse drug effects; Cognition; Iatrogenesis; Memory; Statins.
Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.
Similar articles
-
An assessment of statin safety by neurologists.Am J Cardiol. 2006 Apr 17;97(8A):86C-88C. doi: 10.1016/j.amjcard.2005.12.017. Epub 2006 Feb 3. Am J Cardiol. 2006. PMID: 16581335
-
An assessment by the Statin Intolerance Panel: 2014 update.J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S72-81. doi: 10.1016/j.jacl.2014.03.002. J Clin Lipidol. 2014. PMID: 24793444
-
An assessment by the Statin Muscle Safety Task Force: 2014 update.J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S58-71. doi: 10.1016/j.jacl.2014.03.004. J Clin Lipidol. 2014. PMID: 24793443
-
Statins and cognitive side effects: what cardiologists need to know.Cardiol Clin. 2015 May;33(2):245-56. doi: 10.1016/j.ccl.2015.02.008. Cardiol Clin. 2015. PMID: 25939297 Review.
-
Statins, cardiovascular disease, and drug safety.Am J Cardiol. 2006 Apr 17;97(8A):3C-5C. doi: 10.1016/j.amjcard.2005.12.005. Epub 2006 Jan 25. Am J Cardiol. 2006. PMID: 16581326 Review.
Cited by
-
Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study.CNS Neurosci Ther. 2024 Apr;30(4):e14522. doi: 10.1111/cns.14522. Epub 2023 Nov 10. CNS Neurosci Ther. 2024. PMID: 37950531 Free PMC article.
-
Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS.Front Pharmacol. 2022 Nov 24;13:894685. doi: 10.3389/fphar.2022.894685. eCollection 2022. Front Pharmacol. 2022. PMID: 36506552 Free PMC article.
-
Neurocognitive Impairment in Cardiovascular Disease Patients Taking Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Systematic Review.Cureus. 2022 Oct 31;14(10):e30942. doi: 10.7759/cureus.30942. eCollection 2022 Oct. Cureus. 2022. PMID: 36465767 Free PMC article. Review.
-
Genetic Predisposition to Low-Density Lipoprotein Cholesterol May Increase Risks of Both Individual and Familial Alzheimer's Disease.Front Med (Lausanne). 2022 Jan 11;8:798334. doi: 10.3389/fmed.2021.798334. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35087849 Free PMC article.
-
The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases.Aging Dis. 2021 Dec 1;12(8):1857-1871. doi: 10.14336/AD.2021.0412. eCollection 2021 Dec. Aging Dis. 2021. PMID: 34881073 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
